San Jose BioCube

sanjosebiocube.com

The BioCube provides flexible office space, access to state-of-the-art lab facilities, and business support to promising life science, nanotech, and cleantech startup companies. We are scalable throughout your company’s growth stages. Membership can start with prorated access to our CORE laboratory. It continues by moving your company into the BioCube. From this point, we have the resources needed to build custom facilities within the BioCube complex to match your growing needs.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Diagnostics

AVANTOR® TO COLLABORATE WITH GEMINIBIO TO BRING CUSTOM HYDRATED SOLUTIONS AND CELL CULTURE MEDIA TO BIOPHARMA CUSTOMERS

Avantor | June 24, 2022

news image

Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries has entered into an agreement with GeminiBio to deliver custom hydrated solutions and cell culture media to the biopharma industry. Custom hydrated solutions and cell culture media are critical components of the bioproduction workflow, especially for emerging modalities such as gene therapy. This c...

Read More

Medical

BIO-MANUFACTURING PARTNER BIOELPIDA COMPLETES NEXT PHASE OF BVX-0918 GMP PRODUCTION FOR EU CLINICAL STUDY

BioVaxys | June 09, 2022

news image

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that its Lyon, France-based bioproduction partner, BioElpida ("BioElpida"), has completed the creation of multiple OVCAR-3 cell banks as the next step in the GMP manufacturing process development for BVX-0918, BioVaxys' vaccine for treatment of platinum-resistant ovarian cancer. The OVCAR-3 cell line is mandatory for creating the identity ass...

Read More

Cell and Gene Therapy, MedTech

NKARTA ANNOUNCES UPDATED CLINICAL DATA ON ANTI-CD19 ALLOGENEIC CAR-NK CELL THERAPY NKX019 FOR PATIENTS

Nkarta, Inc. | December 06, 2022

news image

Nkarta, Inc. a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today announced positive updated data from its Phase 1 dose escalation study of NKX019 as monotherapy to treat patients with relapsed or refractory non-Hodgkin lymphoma. Seven of ten patients treated at the higher dose levels in a three-dose regimen showed a complete response including two patients with aggressive large B cell lymphoma one patient with mantle cell lymphoma...

Read More

Medical

PACBIO TRANSFORMS ACCESS TO THE EPIGENOME AND STREAMLINES WORKFLOWS

PacBio | April 23, 2022

news image

PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the release of a transformative capability to detect DNA methylation using the Sequel IIe and Sequel II Systems. This extends PacBio’s unique and highly capable HiFi sequencing technology to now include access to the epigenome, a second layer of genomic information often left unexplored due to fundamental limitations of common sequencing technologies. PacBio’s single-mole...

Read More
news image

Diagnostics

AVANTOR® TO COLLABORATE WITH GEMINIBIO TO BRING CUSTOM HYDRATED SOLUTIONS AND CELL CULTURE MEDIA TO BIOPHARMA CUSTOMERS

Avantor | June 24, 2022

Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries has entered into an agreement with GeminiBio to deliver custom hydrated solutions and cell culture media to the biopharma industry. Custom hydrated solutions and cell culture media are critical components of the bioproduction workflow, especially for emerging modalities such as gene therapy. This c...

Read More
news image

Medical

BIO-MANUFACTURING PARTNER BIOELPIDA COMPLETES NEXT PHASE OF BVX-0918 GMP PRODUCTION FOR EU CLINICAL STUDY

BioVaxys | June 09, 2022

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that its Lyon, France-based bioproduction partner, BioElpida ("BioElpida"), has completed the creation of multiple OVCAR-3 cell banks as the next step in the GMP manufacturing process development for BVX-0918, BioVaxys' vaccine for treatment of platinum-resistant ovarian cancer. The OVCAR-3 cell line is mandatory for creating the identity ass...

Read More
news image

Cell and Gene Therapy, MedTech

NKARTA ANNOUNCES UPDATED CLINICAL DATA ON ANTI-CD19 ALLOGENEIC CAR-NK CELL THERAPY NKX019 FOR PATIENTS

Nkarta, Inc. | December 06, 2022

Nkarta, Inc. a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today announced positive updated data from its Phase 1 dose escalation study of NKX019 as monotherapy to treat patients with relapsed or refractory non-Hodgkin lymphoma. Seven of ten patients treated at the higher dose levels in a three-dose regimen showed a complete response including two patients with aggressive large B cell lymphoma one patient with mantle cell lymphoma...

Read More
news image

Medical

PACBIO TRANSFORMS ACCESS TO THE EPIGENOME AND STREAMLINES WORKFLOWS

PacBio | April 23, 2022

PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the release of a transformative capability to detect DNA methylation using the Sequel IIe and Sequel II Systems. This extends PacBio’s unique and highly capable HiFi sequencing technology to now include access to the epigenome, a second layer of genomic information often left unexplored due to fundamental limitations of common sequencing technologies. PacBio’s single-mole...

Read More